The abstract is read at the publisher; the summary is JClub's.
In healthy infant cynomolgus monkeys and juvenile XLMTM dogs, rAAV8-Des-hMTM1 showed no evidence of hyperbilirubinemia or other liver-associated toxicity after dosing.
- Why it matters: Cholestatic liver failure and deaths in a first-in-human trial for XLMTM raised concerns about hepatobiliary safety that large-animal data could clarify.
- What they did: The study retrospectively analyzed large-animal safety after relatively high doses of rAAV8-Des-hMTM1 in cynomolgus monkeys and canine-version dosing in juvenile XLMTM dogs, measuring liver vector genomes and liver toxicity markers.
- The result: Despite highest vector genomes in liver, rAAV8-Des-hMTM1 was generally well-tolerated, supporting a lack of hepatobiliary toxicity signals in these models.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.